Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AMLwmm2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AMLInvivoscribe Marketing2022-08-16T20:08:13-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-09T17:27:05-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more